FDA Supports Pradaxa Approval, But Without Superiority Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency charges the Sept. 20 Cardiovascular and Renal Drugs Advisory Committee with evaluating the relative benefit of preventing strokes with the increased risk of bleeding posed by Boehringer Ingelheim's dabigatran.